Apr 1 |
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago
|
Apr 1 |
Zai Lab reports Krazati lung cancer study meets primary endpoint
|
Apr 1 |
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
|
Mar 27 |
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
|
Mar 27 |
Novocure climbs after late-stage win for lung cancer therapy
|
Mar 19 |
Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB)
|
Mar 13 |
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
|
Mar 6 |
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
|
Mar 6 |
Zai Lab Announces Participation in March Investor Conference
|
Feb 29 |
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript
|